CDH1 and neoplasm: High molecular weight cytokeratin (CK5/6, CK14 &CK17), and Epidermal growth factor receptor (EGFR), a member of the C-erb B family of tyrosine kinase receptor proteins, are postulated to be an effective therapeutic target(7-9),while E-cadherin, a transmembrane glycoprotein and hallmark of epithelial-to-mesenchymal transition, is mapped to the CDH1 gene located in the Ch16q22.1 locus, the inactivation of which results in larger tumours, higher tumour grades, greater risk of metastasis, and incidence of chemoresistance (10-14).